AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get moving
Target
Upside 114%
Price (€) 4.58
Market Cap (€M) 166
Perf. 1W: 8.27%
Perf. 1M: 32.8%
Perf. 3M: 20.1%
Perf Ytd: 39.0%
10 day relative perf. to stoxx600: 5.19%
20 day relative perf. to stoxx600: 31.9%
Latest21/12/2018

Success of the capital increase

Fact

Crossject has announced that the c.€4m capital increase had been subscribed with, among others, c. 1,656k shares by Gemmes Venture (the group’s historic shareholder, which now controls 30.6% of the share capital) out of a total of c.3.4m new shares. The new number of shares stands at 13.6m and new shares will be listed as from 28 December.


Impact

The capital increase was already included in our numbers. We will only adjust them to account for the conversion of warrants since September that led to a high number of shares pre capital increase.


Updates

28 Nov 18 Financing issue
A €3.9m capital increase

23 Oct 18 Other news/comments
Bond conversion

27 Sep 18 Earnings/sales releases
H1 18: insignificant; some more time needed to ...

05 Sep 18 Target Change
On its way to reaching the market

17 May 18 Latest
Business update

.